Efficacy and Tolerability of Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children: a Comparative Study.

Trial Profile

Efficacy and Tolerability of Fesoterodine and Oxybutynin XL for Overactive Bladder Syndrome in Children: a Comparative Study.

Recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Fesoterodine (Primary) ; Oxybutynin
  • Indications Overactive bladder
  • Focus Adverse reactions
  • Acronyms FOXY
  • Most Recent Events

    • 01 Nov 2017 Planned End Date changed from 1 Sep 2017 to 1 Mar 2018.
    • 01 Nov 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Mar 2018.
    • 27 Nov 2016 Planned number of patients changed from 50 to 60.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top